Onyx @ Union Square: Shankar Musunuri, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
CAR T-cell therapies are expensive and unsustainable - Cytiva are trying to change that
Emmanuel Abate reveals how Cytiva are making cell therapy manufacturing faster, greener, and fit for the future.
Could compressed air be the key to sustainable energy storage?
Hydrostor’s CEO explains how revolutionizing an old technology is helping to create a cheaper and more sustainable energy grid.
How Puro.earth became the first public registry dedicated to carbon removal
Antti Vihavainen reveals the science, standards, and momentum behind the global carbon removal market.
Onyx @ Union Square: Mike Exton, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
The future of fluorescence is smaller, smarter, and more accessible
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Onyx Studio Sessions: Paula Brown Stafford, Allucent
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Onyx @ Union Square: Colleen Cutcliffe, Pendulum
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
"It's like Duolingo for sewing" - how Della Yellow is ushering in the age of circular fashion
A digital community for clothing repairs has high hopes to upskill consumers worldwide and trigger an upcycle revolution.
How Piramal Pharma plans to become a multi-billion dollar business
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
We all want our hospital records in one place. Is Novellia the app to do it?
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act.
Adil's JPM Week VLOG
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Onyx Studio Sessions: Fabian Gerlinghaus, Cellares
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Backed by AstraZeneca, this company is helping radioligand cancer therapies hit the shelves
"Think of us as a critical partner in the ecosystem, ensuring that brilliant innovation doesn’t get stuck in the development phase but actually reaches the patients who need them."
Onyx @ Union Square: Helmy Eltoukhy, Guardant Health
Blood tests for cancer are here, and Guardant Health is leading the charge.
CAR-T can only treat 3% of cancer patients. Mongoose Bio is building for the other 97%
Neil Warma explains how Mongoose Bio is pioneering TCR-T therapies that may last longer, tackle more cancers, and require less from patients.